(Q35101742)

6 August 2017

1 reference

title

Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer (English)

1 reference

Adaptive radiation therapy

6 August 2017

main subject

0 references

1 reference

1 reference

Richard E Peschel

1

1 reference

6 August 2017

John W Colberg

series ordinal

2

1 reference

6 August 2017

publication date

1 April 2003

1 reference

Lancet Oncology Commission

6 August 2017

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

233-241

1 reference

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Definitions of biochemical failure in prostate cancer following radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

The definition of biochemical failure in patients treated with definitive radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Practical application of biochemical failure definitions: what to do and when to do it

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Retrospective comparison of radical retropubic prostatectomy and 125iodine brachytherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Quality of life after radical prostatectomy or watchful waiting.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Disease progression following radical prostatectomy in men with Gleason score 7 tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Palladium-103 brachytherapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Long-term complications with prostate implants: iodine-125 vs. palladium-103.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

The dosimetry of prostate brachytherapy-induced urethral strictures

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Complications after prostate brachytherapy in the Medicare population

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Potency after permanent prostate brachytherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Dosimetric analysis of urinary morbidity following prostate brachytherapy (125I vs. 103Pd) combined with external beam radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Long-term results of treatment for prostate carcinoma by staging pelvic lymph node dissection and definitive irradiation using low-dose rate temporary iridium-192 interstitial implant and external beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Intensity-modulated radiotherapy: current status and issues of interest

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Dose selection for prostate cancer patients based on dose comparison and dose response studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Sexual (dys)function after radiotherapy for prostate cancer: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901035-0

7 January 2021

10.1016/S1470-2045(03)01035-0

Identifiers

DOI

1 reference

6 August 2017

1 reference